Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Kenneth Bate currently holds 8,896 shares of Epizyme, Inc. (EPZM), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Kenneth Bate has been a net seller of EPZM stock. They have purchased $0 and sold $22.4M worth of shares.
Kenneth Bate's most recent insider trade was on Nov 5, 2025, when they sold 1,931 shares at $484.78 per share.
Kenneth Bate serves as Executive at Epizyme, Inc. (EPZM). They have executed 81 insider transactions totaling $22.4M over their tenure at the company.
Kenneth Bate holds the position of Executive at Epizyme, Inc., where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 18 years and currently hold a stake valued at $0.
Kenneth Bate has shown a selling trading pattern, with $0 in total purchases and $22.4M in total sales across all transactions. Their most recent activity indicates a tendency to reduce their position.
The largest transaction by Kenneth Bate was on Nov 5, 2025, when they sold $3.0M worth of MDGL shares. This transaction involved 10,000 shares at $303.79 per share.
Kenneth Bate currently owns 8,896 shares of Epizyme, Inc. (EPZM), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Kenneth Bate's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Kenneth Bate has 81 Form 4 filings on record as an insider at Epizyme, Inc..
Set alerts for Kenneth Bate and 40,000+ other insiders.